Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Merck
Express Scripts
AstraZeneca
McKinsey

Last Updated: January 27, 2023

Eugia Pharma Company Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the competitive landscape for EUGIA PHARMA, and what generic alternatives to EUGIA PHARMA drugs are available?

EUGIA PHARMA has one hundred and forty-two approved drugs.

There is one US patent protecting EUGIA PHARMA drugs. There are seven tentative approvals on EUGIA PHARMA drugs.

There are ten patent family members on EUGIA PHARMA drugs in nine countries and two hundred and sixty-one supplementary protection certificates in fifteen countries.

Summary for Eugia Pharma
International Patents:10
US Patents:1
Tradenames:118
Ingredients:110
NDAs:142
Patent Litigation for Eugia Pharma: See patent lawsuits for Eugia Pharma

Drugs and US Patents for Eugia Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eugia Pharma ERLOTINIB HYDROCHLORIDE erlotinib hydrochloride TABLET;ORAL 216342-002 Jun 22, 2022 AB RX No No See Plans and Pricing See Plans and Pricing
Eugia Pharma DEXMEDETOMIDINE HYDROCHLORIDE dexmedetomidine hydrochloride INJECTABLE;INJECTION 205867-001 Mar 17, 2016 AP RX No No See Plans and Pricing See Plans and Pricing
Eugia Pharma KETOROLAC TROMETHAMINE ketorolac tromethamine SOLUTION/DROPS;OPHTHALMIC 205190-001 Dec 3, 2020 DISCN No No See Plans and Pricing See Plans and Pricing
Eugia Pharma KETOROLAC TROMETHAMINE ketorolac tromethamine INJECTABLE;INJECTION 212939-002 Oct 20, 2020 DISCN No No See Plans and Pricing See Plans and Pricing
Eugia Pharma VECURONIUM BROMIDE vecuronium bromide INJECTABLE;INJECTION 206670-001 Dec 20, 2018 AP RX No No See Plans and Pricing See Plans and Pricing
Eugia Pharma LEVETIRACETAM IN SODIUM CHLORIDE levetiracetam INJECTABLE;INTRAVENOUS 207160-003 Jan 4, 2017 AP RX No No See Plans and Pricing See Plans and Pricing
Eugia Pharma CARBOPLATIN carboplatin INJECTABLE;INTRAVENOUS 205487-001 Mar 28, 2016 AP RX No No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for Eugia Pharma Drugs

Country Patent Number Estimated Expiration
European Patent Office 3139929 See Plans and Pricing
Canada 2948148 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2015171460 See Plans and Pricing
Russian Federation 2016147362 See Plans and Pricing
Japan 6516831 See Plans and Pricing
Australia 2015256331 See Plans and Pricing
Brazil 112016026140 See Plans and Pricing
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for Eugia Pharma Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1189916 2011C/004 Belgium See Plans and Pricing PRODUCT NAME: REGADENOSON; AUTHORISATION NUMBER AND DATE: EU/1/10/643/001 20100906
0275821 01C0035 France See Plans and Pricing PRODUCT NAME: ZOLEDRONIC ACID; NAT REG. NO/DATE: EU/1/01/176/001 20010320; FIRST REG.: LI IKS N 55 463 20001128
2785706 C02785706/01 Switzerland See Plans and Pricing PRODUCT NAME: FOSNETUPITANT, PALONOSETRON.; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68290 01.09.2022
2563920 CR 2019 00001 Denmark See Plans and Pricing PRODUCT NAME: INOTERSEN AND SALT THEREOF, INCLUDING SODIUM SALTS; REG. NO/DATE: EU/1/18/1296 20180710
1856135 2090014-8 Sweden See Plans and Pricing PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE OR SOLVATE OF FOSTAMATINIB OR THE PH ARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113
0863901 PA2004008 Lithuania See Plans and Pricing PRODUCT NAME: ERTAPENEMUM ([4R,5S,6S]-3-[(3S,5S)-5-[(3-KARBOKSIFENIL) AMINO]KARBONIL]-3-PIROLIDINIL]TIO]-6-[(1R)-1HIDROKSIETIL]-4-METIL-7-OKSO-1-AZABICIKLO-[3.2.0]HEPT-2-EN-2-KARBOKSIRUGSTIS; REGISTRATION NO/DATE: 03/8043/3 20030328
0296749 09C0055 France See Plans and Pricing PRODUCT NAME: ANASTROZOLE, EVENTUELLEMENT SOUS LA FORME D’UN SEL D’ADDITION ACCEPTABLE EN MEDECINE PHARMACEUTIQUE; REGISTRATION NO/DATE IN FRANCE: NL 21126 DU 19961227; REGISTRATION NO/DATE AT EEC: 12619/0106 DU 19950811
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.